newsfilter
← Latest News
GlobeNewswire·

Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody